TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE — TOCIDYS

Fibrous Dysplasia of Bone Clinical Trial

Official title:
TREATMENT OF FIBROUS DYSPLASIA OF BONE WITH TOCILIZUMAB AMONG PATIENTS WHO DO NOT RESPOND TO BISPHOSPHONATES. THE TOCIDYS TRIAL.

Status Completed

Clinical Trial Summary

Bone pain due to fibrous dysplasia of bone is usually treated with bisphosphonates. A small proportion of patients fail to respond adequately. Mutated bone cells produce large amounts of Interleukin-6 (IL-6), with increased bone resorption as a result. Inhibition of IL-6 may be of interest to reduce bone resorption and therefore bone pain. TOCIDYS is a placebo-controlled randomized cross-over trial to test the hypothesis that tocilizumab can reduce bone resorption in those patients with fibrous dysplasia who have already received bisphosphonates.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01791842
Study type	Interventional
Source	Hospices Civils de Lyon
Contact
Status	Completed
Phase	Phase 2
Start date	May 5, 2013
Completion date	June 19, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00445575` - Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone	Phase 2/Phase 3
Completed	`NCT05422833` - Effectiveness of Medical Management of Fibrous Dysplasia of Bone.
Recruiting	`NCT06177327` - Hepato-pancreato-biliary Abnormalities in Fibrous Dysplasia of Bone/McCune Albright Syndrome
Recruiting	`NCT03838991` - Epigenetic Regulation in Fibrous Dysplasia of Bone: mirDYS Study.	N/A
Active, not recruiting	`NCT05509595` - Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia	Phase 2